Home > Blog > Pomolive and its Preclinical Studies
Innovation

Pomolive and its Preclinical Studies

Published on 25 of February of 2025

Reading time Reading of 1 min

Pomolive and its Preclinical Studies

All the news about our novelty ingredient

During the past months our preclinical unit has developed several trials to prove the effectiveness of our unique synergistic combination of proprietary apple and olive extracts to control Metabolic Syndrome: Pomolive.

The beneficial effects of Mediterranean diet have been proven in several studies. Based on those researches and our expertise, Natac has developed this new ingredient with pre-clinical studies available and ongoing clinical trials. We are proud to announce the outstanding results obtained from our preclinical studies that support the benefits of the Mediterranean diet on cardiovascular health and Metabolic Syndrome reduction:

After eight weeks of treatment in genetically obese mice receiving Pomolive, the results shown that lumbar adipose tissue (equivalent to visceral adipose tissue in humans) was reduced, as well as glucose and triglyceride levels. These results prove the effectiveness of Pomolive on glucose and lipids management.

bg-left
cta-bg cta-bg

Subscribe to our Newsletter

Receive the latest news on Natac in your email